ReviewChinese medical journal pulmonary and critical care medicine2025
Treatment of allergic bronchopulmonary aspergillosis with biologics.
Review in Chinese medical journal pulmonary and critical care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Review
- High total serum IgE level at diagnosis was associated with a progressive decline in lung function in asthmatic patients with allergic bronchopulmonary mycosis.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2026Article
- [Allergic bronchopulmonary aspergillosis-essential knowledge for radiology].Radiologie (Heidelberg, Germany) · 2026Review
- Identification of Misdiagnosis Factors in Allergic Bronchopulmonary Mycosis Using Explainable Machine Learning.Journal of asthma and allergy · 2026Article
- Review
- Case Report: Omalizumab combined with voriconazole for the treatment of ABPA complicating IPA: a case report.Frontiers in pharmacology · 2025Article
- Comparative Prognosis of Fungal Balls Versus Invasive Pulmonary Mucormycosis.Infection and drug resistance · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with allergic bronchopulmonary aspergillosis (ABPA) respond well to standard treatments (oral corticosteroids and/or antifungals); however, approximately in half of the patients, the condition recurs during tapering or early after treatment discontinuation. To avoid the adverse effects of long-term treatment, biologics targeting immunoglobulin E (IgE), eosinophils, or type 2 immune responses have been used in refractory ABPA. Omalizumab, an anti-IgE antibody, as well as mepolizumab and benralizumab targeting eosinophils has been consistently shown to decrease co-morbid asthma exacerbation and dose of oral corticosteroids. Furthermore, mepolizumab and benralizumab effectively improved chest radiographic abnormalities, such as mucus plugs in the bronchi. Data on dupilumab and tezepelumab are limited; however, they may be effective in patients who are resistant to treatment with omalizumab/mepolizumab/benralizumab. Future studies examining the effects of these biologics in preventing the recurrences/exacerbations of ABPA are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.